Progress in the management of acute colchicine poisoning in adults

Jiacheng Wu1 · Zhenning Liu

Received: 8 April 2022 / Accepted: 7 August 2022 / Published online: 26 August 2022 © The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI) 2022

Abstract
Colchicine is a tricyclic, lipid-soluble alkaloid which has long been used to treat gout and many immunological diseases. Due to its narrow therapeutic window and long half-life of elimination, colchicine overdose occurs occasionally. Unfortunately, some patients lost their lives because of colchicine overdose or suicide. Acute colchicine poisoning can lead to original gastrointestinal disorders, shock, progressive multiple organ failure, and myelosuppression. Although many researchers in the world performed lots of research, there are currently no specific antidotes for colchicine poisoning. Meanwhile, there are no management guidelines to treat patients with acute colchicine poisoning until now. Herein, we systematically elaborate on the clinical features and progress in the management of acute colchicine poisoning in adults according to the previous literature. This paper will provide some valuable and available information for clinicians.

Keywords Colchicine poisoning · Multiple organ dysfunction · Myelosuppression · Management strategy · Blood perfusion · Extracorporeal life support

Introduction
Colchicine is a naturally occurring alkaloid extracted from the plants Colchicum autumnale and Gloriosa superba [1]. Colchicine is also an ancient drug which was originally used to treat gout for centuries. Due to its toxicity, the use of colchicine is clinically limited. In recent years, it has been approved by the Food and Drug Administration (FDA) to treat many autoinflammatory diseases including Behcet’s disease, Familial Mediterranean fever, osteoarthritis, and certain spondyloarthropathy [2, 3]. Interestingly, new emerging evidence suggests that colchicine can significantly reduce the risk of mortality and hospitalization in patients with COVID-19 [3, 4]. The administration with a recommended dose of colchicine is safe for patients. The most common adverse effects of colchicine in a therapeutic dose are gastrointestinal disturbance including diarrhea, vomiting, and nausea, occurring in less than 10% of patients [1]. Excessive doses of colchicine would cause serious toxicity.

Acute toxicity by colchicine is not common but is followed by a high mortality rate. Although deaths resulting from the oral ingestion of overdose colchicine are reported every year, there are no management guidelines or specific antidotes currently. It is essential for clinicians to recognize and treat colchicine poisoning. Herein, the pharmacologic properties and toxic effects of colchicine are described. Meanwhile, the previous reports on acute colchicine overdose in adults were summarized and the management of colchicine poisoning was systematically illustrated. This paper would provide some valuable information for clinicians to treat patients with acute colchicine poisoning effectively.

Pharmacologic properties
Colchicine is a small molecule with a molecular weight of 399 Da. It exerts an anti-inflammatory effect due to the ability to suppress neutrophil activity. In addition, colchicine can impair mitosis by inhibiting microtubule devices which are necessary for the maintenance of cellular homeostasis and thereby causing cell injury [5, 6].

Colchicine can spread rapidly and widely to all tissues shortly after oral administration, accumulating in bone marrow, kidney, heart, liver, intestinal mucosa, and brain [7]. Colchicine is metabolized to 2- and 3-demethylcolchicine
by the CYP 3A4 isofrom of cytochrome P450 in hepatocytes, followed by biliary excretion [8]. Colchicine and its metabolites undergo significant enterohepatic re-circulation which may further lead to its retention in the body [9]. It has a short initial distribution phase, with a plasma half-life of 1–2.7 h. Its volume of distribution ($V_d$) can reach 7–10 L/kg in a therapeutic dose, which is significantly larger than the extracellular compartment [7]. Notably, its $V_d$ can even reach up to 21 L/kg in overdose [10]. It indicates that colchicine can be distributed to nearly all tissues. Its binding to albumin is moderate (10–50%) in therapeutic doses [6,11]. Colchicine and its metabolites are mainly eliminated through the liver. The kidneys contribute only 10–20% of the total colchicine clearance [12]. The elimination half-life of colchicine is 9.3–30 h in humans [11,13]. In healthy volunteers given oral colchicine daily, the plasma levels of colchicine can reach the steady-state within a few days [13]. Therefore, the time to stable plasma levels is consistent with the long elimination half-life.

It is commonly accepted that CYP3A4 plays a vital role in colchicine metabolism and elimination. In addition to CYP3A4, P-glycoprotein that is an ATPase efflux pump can extrude colchicine from the enterocytes to prevent gastrointestinal absorption [1]. Both CYP3A4 and P-glycoprotein are mainly responsible for colchicine metabolism. Therefore, the levels of CYP3A4 and P-glycoprotein would determine the content of colchicine in the human body. From another point of view, the drugs which inhibit or induce the activities of CYP3A4 and P-glycoprotein would affect the efficacy or toxicity of colchicine. The possible inducers and inhibitors of CYP 3A4 or P-glycoprotein [1,14,15] are shown in Table 1. Accordingly, when concurrent treatment with a strong inhibitor of CYP3A4 or P-glycoprotein is required, it is recommended that the colchicine dose should be reduced to prevent its toxicity.

### Colchicine toxicity

Due to its narrow therapeutic window (1.2–2.4 mg/day in adults) [6] and long half-life of elimination mentioned above, the clinical application of colchicine is limited to some extent. The maximum oral doses of colchicine for familial Mediterranean fever (FMF) and acute gout recommended by the Food and Drug Administration (FDA) are 2.4 mg/day and 1.8 mg/day [6], respectively. Therefore, oral ingestion exceeding the maximum oral dose of 2.4 mg/day is commonly considered to be a colchicine overdose. Acute oral ingestion exceeding 0.5 mg – 0.8 mg/kg of colchicine is considered to be fatal [6,16]. Nevertheless, there is no clear-cut line between nontoxic, toxic, and lethal doses of colchicine in human [6].

Colchicine overdose can inhibit cell division by fixing the intracellular tubulin and disrupting the mitosis and transport systems. Thus, the organs with active cell proliferation, such as the gastrointestinal tract, bone marrow, and hair follicles, are often the most susceptible to the toxic effects of colchicine [17,18]. Moreover, colchicine overdose can lead to multiple organ dysfunction by inhibiting cell mitosis progress, particularly in the liver and kidneys. According to previous reports, the fatality rate of acute colchicine poisoning may range from 14.3 to 25.6% [19,20].

### Table 1 Drugs affecting colchicine toxicity

| Interactions with colchicine | Representative drugs |
|-----------------------------|----------------------|
| CYP3A4 inhibitors (↑ toxicity) | Almorexant, alpha, amiodarone, ampronavir, aprepitant, atazanavir, boceprevir, casopitant, ceritinib, chloramphenicol, cimetidine, ciprofloxacin, clarithromycin, clotrimazole, cobicistat, convivaptan, crizotinib, cyclosporine, dalfopristin, danazol, darunavir, dasatinib, deferasirox, delavirdine, diltiazem, dronedarone, erythromycin, fluconazole, fluoxetine, fluvoxamine, fosamprenavir, fosaprepitant, fusidic acid, grapefruit juice, idelalisib, imatinib, indinavir, interferon alpha, isoniazid, itraconazole, ketoconazole, lapatinib, lopinavir, lomitapide, miconazole, natural, nefazodone, nelfinavir, paroxetine, posaconazole, propoxyphene, quinupristin, ritonavir, saquinavir, simvastatin, tacrolimus, verapamil, voriconazole, etc |
| P-glycoprotein inhibitors (↑ toxicity) | Atorvastatin, budesonide, clarithromycin, cyclosporine, diltiazem, erithromycin, grapefruit juice, hydrocortisone, itraconazole, ketoconazole, lovastatin, propafenone, quinidine, ranolaze, saquinavir, simvastatin, tacrolimus, verapamil, voriconazole, etc |
| CYP3A4 inducers (↓ toxicity) | Aminoglutethimide, armodafinil, barbiturates, bexarotene, bosentan, carbamazepine, dabrafenib, dexamethasone, efavirenz, enzalutamide, eslicarbazepine, etravirine, fosamprenavir, fosphenytoin, griosefolvin, lumacaftor, modafinil, nafcillin, nevirapine, oxcarbazepine, phenytoin, primidone, rifabutin, rifampin, rifapentine, St. John’s wort extract, quercetin, rifabutin, etc |
| P-glycoprotein inducers (↓ toxicity) | Phenytoin, curcumin, carbamazepine, genistein, St. John’s wort extract, quercetin, rifabutin, etc |
Literature review

Clinical reports in adults between January 2001 and December 2021 were sought in PubMed and Web of Science using the following search terms: ("colchicine poisoning" OR "colchicine overdose"). Data concerning the dosage of colchicine, clinical manifestations, management, and outcomes were extracted in this paper. Meanwhile, case series of acute colchicine poisoning were also reviewed. The reports which met any of the following criteria were included in this study: (1) age ≥ 18 years old; (2) patients had a definite history of suicidal poisoning with colchicine or overdose after colchicine misuse treatment; (3) time interval between ingestion and admission to hospital ≤ 72 h. The reports were excluded based on the following criteria: (1) colchicine poisoning was confirmed by autopsy; (2) patients suffered from accidental poisoning with the plants containing colchicine; (3) with other drugs or toxicants poisoning; (4) incomplete description of the clinical manifestations and therapeutic strategy of colchicine poisoning.

As shown in Fig. 1, a total of 67 cases were collected in the examined period. Forty-seven patients were excluded based on the exclusion criteria. Consequently, a total of 20 cases extracted from nineteen articles were summarized in Tables 2 and 3. Among the enrolled cases, four cases were extracted from case series of three articles [5, 16, 21]. The average age of the patients enrolled in this study was 35.75 ± 14.83 years shown in Table 3. The male to female ratio of the patients was 12/8, but there was no gender-dependent effect using Fisher’s exact test (P > 0.05) according to the collected data. In terms of the patient’s living area, half of them were from Asian countries (Table 2).

Clinical features

As described in the previous literatures, the typical symptoms of acute colchicine poisoning can be separated into three sequential and overlapping phases [22]. Phase I (within 24 h post-ingestion) reflects gastrointestinal mucosal damage characterized by abdominal pain, severe vomiting, diarrhea, and gastrointestinal hemorrhage. Phase II (generally 1–7 days post-ingestion) is characterized by metabolic acidosis, shock, myelosuppression, and multi-organ dysfunction including oliguric renal failure, liver dysfunction, and respiratory failure. Phase III (7–21 days post-ingestion) is characterized by bone marrow hematopoietic recovery and resolution of organ system derangements. It is worth noting that most of the deaths occur 7–10 days after oral ingestion [23]. Metabolic acidosis and multiple organ dysfunction are closely associated with substantial morbidity and mortality. Once multiple organ failure occurs, the mortality rate would be close to 100% [5, 16].

As shown in Tables 2 and 3, approximately 70% of patients developed gastrointestinal symptoms and metabolic acidosis; most patients suffered from multiple organ dysfunction including acute kidney injury (75%), acute respiratory failure (80%), hepatic dysfunction (60%), and acute myocardial injury (80%); myelosuppression including anemia, leucopenia, and thrombocytopenia occurred in around half of the patients. The mortality rate for patients with colchicine poisoning is 50%.

Management

Due to the high mortality rate of acute colchicine poisoning, prompt and effective treatment is essential with the aim of ameliorating the toxic effects of colchicine. Considering that there are no specific antidotes for colchicine, the management strategy for acute colchicine poisoning including prevention of colchicine absorption, blood purification, and supportive therapy is described in detail as follows.

Prevention of colchicine absorption

Gastric lavage is effective within the first 1–2 h post-ingestion to remove residual toxic substances in the stomach [24]. In addition, gastric decontamination with activated charcoal is recommended in most guidelines for acute toxicant poisoning. It was demonstrated that 5 g of activated charcoal can effectively bind up to 90% of approximately 10 mg of colchicine [25]. Activated charcoal with a small volume of liquid may be administered through the orogastric tube to...
| Authors                      | Gender | Age (Y) | Cause       | Dosage (serum colchicine level) | Time interval between ingestion and admission (h) | Clinical symptoms                                                                 | Organ dysfunction                                                                 | Therapy                                                                 | Outcome | Country   |
|-----------------------------|--------|---------|-------------|---------------------------------|---------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------------------------------------------------------|---------|-----------|
| Maxwell, M. J. et al. [26]  | M      | 41      | Overdose    | 26.5 mg                         | 24–48                                             | Abdominal pain, diarrhea, vomiting, Acute myocardial injury, acute respiratory failure, AKI, metabolic acidosis | Mechanical ventilation                                                        | Death                                      | UK       |
| Arroyo, M. P. et al. [58]   | M      | 48      | Overdose    | 18 mg                           | 30                                                | Diarrhea, nausea, vomiting, Acidosis, acute myocardial injury, acute respiratory failure, AKI, anemia, coagulation disorders, leukopenia, rhabdomyolysis, thrombocytopenia | Antibiotics, blood component transfusion, fluid therapy, G-CSF, hemodialysis, mechanical ventilation | Death                                      | USA      |
| Jayaprakash, V. et al. [21] | M      | 20      | Suicide     | 40 mg                           | 12                                               | Abdominal pain, diarrhea, Acute myocardial injury, acute respiratory failure, AKI, coagulation disorders | Activated charcoal, mechanical ventilation                                          | Death                                      | New Zealand |
| Huang, W.H., et al. [59]    | M      | 48      | Overdose    | > 10 mg                         | 72                                               | Abdominal pain, diarrhea, AKI, liver damage          | Fluid therapy                                                                 | Recovery                                   | China     |
| Iosifina, I., et al. [55]   | F      | 47      | Suicide     | 90 mg                           | 1                                                | Abdominal pain, diarrhea, nausea, positive blood / sputum culture, vomiting, Acidosis, acute myocardial injury, acute respiratory failure, AKI, anemia, coagulation disorders, leukopenia, liver damage, rhabdomyolysis, thrombocytopenia | Activated charcoal, antibiotics, blood component transfusion, fluid therapy, G-CSF, hemodialysis, NAC | Recovery                                   | Canada    |
| Herrán-Monge, R., et al. [60]| M      | 52      | Overdose    | 40 mg                           | 8                                                | Abdominal pain, diarrhea, positive blood/urine culture, Acidosis, acute myocardial injury, acute respiratory failure, AKI, coagulation disorders, leukopenia, liver damage, rhabdomyolysis, thrombocytopenia | Activated charcoal, antibiotics, antifungal therapy, gastric lavage, G-CSF, hemodialysis, mechanical ventilation | Death                                      | Spain     |
| Jouffroy, R., et al. [46]   | M      | 51      | Suicide     | 17 mg (9.7 nmol/L)              | 24                                               | Shock, Acute myocardial injury, acute respiratory failure, AKI                      | ECLS, hemodialysis, Recovery mechanical ventilation                           | Recovery                                   | France    |
| Authors                          | Gender | Age (Y) | Cause    | Dosage (serum colchicine level) | Time interval between ingestion and admission (h) | Clinical symptoms                                      | Organ dysfunction                                      | Therapy                                                                 | Outcome | Country |
|---------------------------------|--------|---------|----------|--------------------------------|-------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------|------------------------------------------------------------------------|---------|---------|
| Erden, A., et al. [16]          | F      | 23      | Suicide  | 50 mg                          | 4                                               | Abdominal pain, diarrhea, nausea, vomiting          | Acidosis, acute myocardial injury, acute respiratory failure, AKI, coagulation disorders, rhabdomyolysis | Activated charcoal, blood component transfusion, gastric lavage, hemodialysis, mechanical ventilation | Death   | Turkey  |
| Fernández, S., et al. [61]      | M      | 34      | Suicide  | 30 mg                          | 12                                              | Abdominal pain, vomiting, positive blood culture    | Acidosis, acute myocardial injury, acute respiratory failure, AKI, coagulation disorders, leucopenia, liver damage, rhabdomyolysis, thrombocytopenia | Antibiotics, fluid therapy, G-CSF, hemodialysis, mechanical ventilation | Death   | Spain   |
| Aghabiklooeei, A., et al. [5]    | F      | 37      | Suicide  | 38 mg                          | 8                                               | Abdominal pain, nausea, vomiting                    | Acidosis, acute myocardial injury, acute respiratory failure | Activated charcoal, gastric lavage, mechanical ventilation | Death   | Iran    |
|                                 | F      | 25      | Suicide  | 25 mg                          | 4                                               | Vomiting                                            | Leucopenia, thrombocytopenia                          | Activated charcoal, blood component transfusion, G-CSF                  | Recovery | Iran    |
| Shuttleworth, E., et al. [51]    | M      | 19      | Suicide  | 50 mg                          | 2                                               | Vomiting                                            | Anemia, coagulation disorders, leucopenia, thrombocytopenia | Antibiotics, fluid therapy                                       | Recovery | UK      |
| Lev, S., et al. [53]             | F      | 18      | Suicide  | 18 mg                          | 72                                              | Abdominal pain, diarrhea, vomiting                  | Acidosis, acute respiratory failure, anemia, coagulation disorders, leucopenia, liver damage, rhabdomyolysis, thrombocytopenia | Antibiotics, blood component transfusion, G-CSF, mechanical ventilation, NAC | Recovery | Israel  |
| Authors                  | Gender | Age (Y) | Cause              | Dosage (serum colchicine level) | Time interval between ingestion and admission (h) | Clinical symptoms                                      | Organ dysfunction                                                                 | Therapy                                                                                      | Outcome | Country  |
|-------------------------|--------|---------|--------------------|---------------------------------|-------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------|----------|
| Hirayama, I., et al.    | F      | 18      | Overdose           | 15 mg                           | < 24                                            | Abdominal pain, diarrhea                           | Acidosis, acute myocardial injury, acute respiratory failure, AKI, anemia, coagulation disorders, leukopenia, liver damage, thrombocytopenia | Antibiotics, antifungal therapy, blood perfusion, CRRT, Fluid therapy, G-CSF, mechanical ventilation | Recovery | Japan    |
| Zhong, H., et al.       | F      | 19      | Suicide            | 40 mg                           | 44                                              | Abdominal pain, diarrhea, vomiting                 | Acidosis, acute myocardial injury, acute respiratory failure, AKI, anemia, coagulation disorders, liver damage, thrombocytopenia | Antibiotics, blood components transfusion, CRRT, fluid therapy, hemoperfusion              | Recovery | China    |
| Fu, M., et al.          | M      | 56      | Overdose           | 12 mg                           | 40                                              | Abdominal pain, diarrhea, nausea, vomiting         | Acidosis, acute myocardial injury, acute respiratory failure, AKI, coagulation disorders, liver damage, rhabdomyolysis | Antibiotics, blood components transfusion, CRRT, fluid therapy, gastric lavage, G-CSF, mechanical ventilation | Death   | China    |
| Sun, Y. et al.          | M      | 38      | Suicide            | 80 mg                           | 4                                               | Diarrhea, nausea, vomiting                         | Acute myocardial injury, coagulation disorders, liver damage, leukopenia, thrombocytopenia | Antibiotics, blood component transfusion, CVVHDF, fluid therapy, gastric lavage, hemoperfusion, recombinant human thrombopoietin, Vitamin K | Recovery | China    |
| Authors          | Gender | Age (Y) | Cause         | Dosage (serum colchicine level) | Time interval between ingestion and admission (h) | Clinical symptoms                                                                 | Organ dysfunction                                                                 | Therapy                                                                 | Outcome | Country  |
|------------------|--------|---------|---------------|-------------------------------|-----------------------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------|---------|----------|
| Jiang, Q. et al. [66] | F      | 23      | Suicide       | 50 mg                         | 48                                            | Abdominal pain, diarrhea, nausea, vomiting positive blood/sputum culture, rhabdomyolysis, | Acidosis, acute myocardial injury, acute respiratory failure, AKI, anemia, coagulation disorders, leucopenia, liver damage, thrombocytopenia | Antibiotics, antifungal therapy, blood component transfusion, CVVHDF, fluid therapy, G-CSF, hemoperfusion, mechanical ventilation, plasma exchange, recombinant human thrombopoietin | Recovery | China    |
| Cozza, J., et al. [22] | M      | 32      | Overdose      | 32.4 mg (9.6 ng/mL)           | 44                                            | Abdominal pain, diarrhea, nausea, positive blood culture, vomiting              | Acidosis, acute myocardial injury, acute respiratory failure, AKI, anemia, coagulation disorders, leucopenia, liver damage, rhabdomyolysis, thrombocytopenia | Activated charcoal, antibiotics, blood component transfusion, fluid therapy, gastric lavage, G-CSF, hemodialysis, mechanical ventilation, NAC | Death   | USA      |
| Seixas, R., et al. [52] | M      | 66      | Suicide       | 90 mg                         | 12                                            | Dizziness                                                                       | Acidosis, acute myocardial injury, acute respiratory failure, AKI, coagulation disorders, liver damage | Activated charcoal, antibiotics, CVVH, gastric lavage, mechanical ventilation, NAC | Death   | Portugal |

AKI acute kidney injury, CRRT continuous renal replacement therapy, CVVH continuous venous-venous hemofiltration, CVVHDF continuous venous-venous hemodiafiltration, ECLS extracorporeal life support, G-CSF granulocyte-colony stimulating factor, NAC N-acetylcysteine
promote the efficiency of decontamination via absorption. Hence, once the history of colchicine overdose or suicide with colchicine is definite, gastric lavage with activated charcoal should be used promptly after oral ingestion. Gastric lavage should be performed if a high dose of colchicine is ingested, preferably within < 60 min of the ingestion [26]. More importantly, blood drug concentration vs time curve displaying two peaks within 6 h of administration is present [27]. It is possibly associated with a second absorption site or enterohepatic recirculation. Considering the rapid absorption in the gastrointestinal tract and extensive enterohepatic recirculation, gastric lavage and catharsis with multiple doses of activated charcoal can be repeatedly used to continuously remove residual toxicants in the gastrointestinal tract for 48–96 h [28]. The elimination of colchicine in the gastrointestinal tract can prevent intestinal mucosal cell injury from long-time exposure to colchicine.

### Fluid supportive therapy

In addition to gastric lavage and activated charcoal, early and active fluid resuscitation are essential for the treatment of patients with colchicine poisoning due to gastrointestinal fluid loss [29]. Severe dehydration may result in the reduction of renal perfusion leading to acute kidney injury (AKI) with electrolyte and acid–base imbalances. Fluid and electrolyte supplementation can promote the removal of colchicine through the kidneys and improve renal perfusion/hemodynamics [30].

Fluid resuscitation was emphasized in many cases of reports of colchicine poisoning, but the management strategies of fluid supportive therapy were not described in detail. It is accepted the main goals of fluid resuscitation are to restore lost fluid volume and provide adequate tissue perfusion. Both balanced crystalloids (e.g., lactated Ringer’s, Plasma-Lyte) and saline are widely used in clinical practice. Balanced crystalloids are solutions in which including sodium, potassium, chloride, and bicarbonate buffers closer to that of extracellular fluid [31]. According to the previous literatures [32–34], the routine use of balanced crystalloids is greatly beneficial for critically ill patients. Compared with saline, the intravenous fluid administration of balanced crystalloids may cause a decrease in all-cause mortality and incidence of renal insufficiency [33]. Particularly, hyperkalemia is a relative contraindication to the use of balanced crystalloids [32]. According to the previous literatures [32–34], the routine use of balanced crystalloids is greatly beneficial for critically ill patients. Compared with saline, the intravenous fluid administration of balanced crystalloids may cause a decrease in all-cause mortality and incidence of renal insufficiency [33].

Fluid resuscitation was emphasized in many cases of reports of colchicine poisoning, but the management strategies of fluid supportive therapy were not described in detail. It is accepted the main goals of fluid resuscitation are to restore lost fluid volume and provide adequate tissue perfusion. Both balanced crystalloids (e.g., lactated Ringer’s, Plasma-Lyte) and saline are widely used in clinical practice. Balanced crystalloids are solutions in which including sodium, potassium, chloride, and bicarbonate buffers closer to that of extracellular fluid [31]. According to the previous literatures [32–34], the routine use of balanced crystalloids is greatly beneficial for critically ill patients. Compared with saline, the intravenous fluid administration of balanced crystalloids may cause a decrease in all-cause mortality and incidence of renal insufficiency [33]. Particularly, hyperkalemia is a relative contraindication to the use of balanced crystalloids [32]. According to the previous literatures [32–34], the routine use of balanced crystalloids is greatly beneficial for critically ill patients. Compared with saline, the intravenous fluid administration of balanced crystalloids may cause a decrease in all-cause mortality and incidence of renal insufficiency [33]. Particularly, hyperkalemia is a relative contraindication to the use of balanced crystalloids [32].

| Table 3 Characteristics of acute colchicine poisoning in adults (n = 20) |
|-----------------------------|-----------------------------|
| **Age (years)**              | **Mean ± standard deviation** 35.75 ± 14.83 |
| Male/female                  | 12/8                        |
| **Dosage (mg)**              | **Median (interquartile range)** 35.2 (18.00, 50.00) |
| **Time interval between ingestion and admission (h)** | **Median (interquartile range)** 18.0 (5.00, 43.00) |
| **Clinical symptoms, n (%)** | **Abdominal pain** 14 (70%) |
| Diarrhea                     | 14 (70%)                    |
| Dizziness                    | 1 (5%)                      |
| Nausea                       | 8 (40%)                     |
| Shock                        | 1 (5%)                      |
| Vomiting                     | 14 (70%)                    |
| Positive blood culture       | 5 (25%)                     |
| Positive sputum culture      | 2 (10%)                     |
| Positive urine culture       | 1 (5%)                      |
| **Organ dysfunction, n (%)** | **Acute myocardial injury** 16 (80%) |
| Acidosis                     | 14 (70%)                    |
| Acute kidney injury          | 15 (75%)                    |
| Acute respiratory failure    | 16 (80%)                    |
| Anemia                       | 8 (40%)                     |
| Coagulation disorders        | 15 (75%)                    |
| Leucopenia                   | 11 (55%)                    |
| Liver damage                 | 12 (60%)                    |
| Rhabdomyolysis               | 9 (45%)                     |
| Thrombocytopenia             | 12 (60%)                    |
| **Therapy, n (%)**           | **Activated charcoal** 8 (40%) |
| Antibiotics                  | 13 (65%)                    |
| Antifungal therapy           | 3 (15%)                     |
| Blood component transfusion  | 8 (40%)                     |
| Continuous renal replacement therapy | 13 (65%) |
| Extracorporeal life support  | 1 (5%)                      |
| Fluid therapy                | 11 (55%)                    |
| Gastric lavage               | 8 (40%)                     |
| Granulocyte-colony stimulating factor | 10 (50%) |
| Hemoperfusion                | 3 (15%)                     |
| Mechanical ventilation       | 14 (70%)                    |
| N-acetylcysteine             | 5 (25%)                     |
| Plasma exchange              | 1 (5%)                      |
| Recombinant human thrombopoietin | 2 (10%)              |
| Vitamin K                    | 1 (5%)                      |
| **Outcome**                  | **Death/recovery** 10/10    |
In an abundant diuresis would increase colchicine elimination, thereby increasing therapeutic efficacy in the future. However, more experimental or clinical data is needed to evaluate the potential for the treatment of acute colchicine poisoning. Much emphasis is placed on the clearance of this compound. As shown in Table 2, herein, diuresis remains uncertain in a dog with colchicine overdose [30], there are no clinical reports in human studies. Further studies are needed to certify the efficacy of IVLE.

**Intravenous lipid emulsion (IVLE)**

Colchicine is a lipophilic compound. In theory, lipophilic substances can be removed from the blood using IVLE. Although it was reported that IVLE was successfully administered to facilitate colchicine clearance in a dog with colchicine overdose [30], there are no clinical reports in human studies. Further studies are needed to certify the efficacy of IVLE.

**Diuresis**

In addition to the liver, the kidney contributes to < 20% of the clearance. According to the retrospective study reported by Lu et al. [20], diuresis was performed in patients with poisoning doses > 0.5 mg/kg. Furthermore, maintaining an abundant diuresis would increase colchicine elimination [10]. However, diuresis was not mentioned in the case series as shown in Table 2. Herein, diuresis remains uncertain for the treatment of acute colchicine poisoning. Much more experimental or clinical data is needed to evaluate its therapeutic efficacy in the future.

**Blood purification**

Colchicine can be rapidly absorbed by the jejunum and ileum, and peak plasma concentrations would reach the first peak level at time 0.5–1.5 h after oral ingestion [37]. Colchicine would be widely distributed throughout the body. Unfortunately, there are no expert recommendations on blood purification for colchicine poisoning. Considering the apparent volume of distribution and mild-moderate plasma protein-binding rate, hemoperfusion and hemodialysis have no therapeutic effect [9, 26, 38].

The therapeutic effects of plasma exchange (PE) [39, 40] and continuous veno-venous hemofiltration (CVVHDF) [38] were uncertain and need further clinical verification. Matthias et al. reported that plasma exchange did not significantly remove colchicine from the whole body of the poisoned patient [40]. The probable reason for the failure of plasma exchange is the redistribution of colchicine from plasma to tissue compartments [40]. Notably, PE could not only remove metabolic wastes but also improve the coagulation function by replenishing coagulation factors and fibrinolytic proteins. Therefore, early plasma exchange was used to treat adults or children with high doses of colchicine [39, 41]. PE is beneficial to the recovery of the colchicine-poisoned patient to some extent.

CVVHDF did not show satisfactory efficacy, since only a small amount of colchicine was removed from the body [20]. Viewed from another perspective, CVVHDF can not only remove inflammatory mediators and excessive fluid load but also regulate electrolyte and acid–base disorders. It exerts a beneficial effect on cardiac and renal function. Although PE and CVVHDF only eliminated a small amount of colchicine, early PE combined with CVVHDF improved the prognosis [20]. Hence, more clinical studies are needed to determine whether the two therapeutic methods can be used to treat patients with colchicine overdose.

**Extracorporeal life support (ECLS)**

Colchicine toxicity can result in multiple organs failure including acute respiratory failure and cardiogenic shock with a high mortality rate [42]. Acute respiratory failure accounted for about one-third of complications [43]. Acute respiratory distress syndrome (ARDS) may develop as a severe complication of hypovolemic shock or sepsis due to the direct injury to the pulmonary vasculature. As shown in Table 2, mechanical ventilation was performed in about 60% of patients with respiratory failure. Mechanical ventilation is essential for improving respiratory function and maintaining oxygenation, especially for patients with an overdose of colchicine. Moreover, colchicine can impair myocardial function characterized by cardiogenic shock and malignant arrhythmia including complete atrioventricular block, asystole, and ventricular tachycardia [44]. Colchicine results in histological changes in myocytes and affects cardiac impulse generation and conduction [44]. Extracorporeal life support (ECLS) is a major supportive treatment against refractory cardiogenic shock caused by any stimulus. ECLS, also known as extracorporeal membrane oxygenation (ECMO), can be used as a “bridge to recovery”. ECLS can not only maintain oxygenation of the organs but also overcome the refractory cardiogenic shock phase. Much evidence indicates that ECLS can be recommended as a routine supportive treatment for fatal colchicine poisoning [42, 45, 46].

**Improvement of hematopoiesis**

Bone marrow hematopoiesis suppression is an extremely serious complication of acute colchicine poisoning. Prophylactic platelet transfusion is beneficial for the prevention of...
spontaneous bleeding in acute colchicine-poisoned patients. In addition, elective central venous catheter placement is essential for these patients with acute colchicine poisoning who need fluid resuscitation or blood perfusion. Hence, if platelet counts in the peripheral blood < 20 × 10⁹/L, platelet transfusion is recommended [20, 47]. Likewise, if hemoglobin levels < 60 g/L, red blood cells should be transfused. If plasma fibrinogen concentration dropped to < 1.5 g/L, human fibrinogen may be given [20]. Fresh frozen plasma can be transfused to supplement clotting factors with the aim of improving coagulation function [20]. Blood transfusion is beneficial for recovery.

In addition, granulocytogenesis is remarkably suppressed by colchicine overdose. Recombinant human granulocyte-colony stimulating factor (G-CSF) can stimulate the proliferation and differentiation of granulocytes, further enhancing the function of mature granulocytes [48]. It can effectively reduce the risk of sepsis in patients with colchicine overdose [23, 48]. Recombinant human thrombopoietin (TPO) has been demonstrated to increase platelet count in patients with immune thrombocytopenia [49]. TPO should be administrated to the colchicine-poisoned patients, if platelet counts in the peripheral blood < 50 × 10⁹/L [20]. The application of G-CSF and TPO can attenuate the severity and shorten the duration of neutropenia and thrombocytopenia [20].

**Antimicrobial therapy**

Severe colchicine poisoning can lead to myelosuppression followed by leukopenia and immune dysfunction with an increased risk of infection. Many previous studies illustrated that patients with colchicine intoxication were susceptible to infections due to the change in granulocyte counts and inhibition of leukocyte functions [50–52]. Antimicrobial therapy is essential for patients with colchicine poisoning at an appropriate time. Regrettably, this point is not described in detail according to the published studies. As shown in Tables 2 and 3, only five patients (25%) of the patients with colchicine poisoning had positive blood cultures. Thirteen patients (65%) received antibiotics and three patients (15%) received antifungal therapy. β-lactam antibiotics were prescribed in 62% of patients with antibiotherapy. Ideally, the selection of antimicrobial agents should be based on the microbial culture followed by antimicrobial susceptibility testing results. However, microbial culture would take three to five days to furnish a definitive result. It would contribute to a delay in medical treatment. Therefore, antimicrobial agents are selected empirically at the right time based on the clinical manifestations and inflammatory biomarkers [e.g., C-reactive protein (CRP) and procalcitonin] in the absence of positive cultures [20, 52]. Particularly, it should also be noted that inappropriate antibiotics might select microbial/fungal resistance. Future investigations in this area are needed.

**N-acetylcysteine**

It is well known that colchicine can induce endothelial and mucosal damage due to oxidative stress [53]. N-Acetylcysteine (NAC) exhibits its antioxidant ability by reducing oxidant-induced cell damage and apoptosis [54]. NAC was previously used in the treatment of acetaminophen poisoning, pulmonary fibrosis, and cystic fibrosis [55]. Likewise, treatment with NAC significantly improved oxidative stress-induced cellular damage by colchicine [53]. NAC was used to treat 25% of patients with colchicine poisoning (Tables 2 and 3). Much more evidence is needed to certify the efficacy of NAC in the future.

**Potential antidotes**

Currently, there are no clinically available antidotes for colchicine toxicity. Colchicine-specific antigen-binding fragments (Fabs) were previously demonstrated to bind to colchicine with a high affinity and enable redistribution and elimination of colchicine [2]. A recent study demonstrated early administration of colchicine-specific Fab was highly effective in preventing severe toxicity in a porcine model [56]. The colchicine-specific Fab fragments were successfully to treat a patient who attempted suicide with 60 mg colchicine [2]. Nevertheless, colchicine-specific Fab is not commercially available as yet. In addition, another new discovery showed that an engineered lipocalin (Lcn2) that tightly complexes colchicine can be used as an effective antidote to scavenge colchicine and reverse its toxic effects [57]. Much more clinical studies are needed to determine whether the two methods can be applied to human poisoning.

**Conclusions**

In summary, colchicine poisoning with a high mortality rate is a rare but life-threatening event. Patients with overdose of colchicine may present with gastrointestinal disorders followed by multiple organ failure, myelosuppression, shock, and acid–base imbalance. Early gastric lavage and catharsis with multiple doses of activated charcoal can be repeated and used to remove colchicine in the gastrointestinal tract. Fluid supplementation can promote the elimination of colchicine through the kidneys. Early PE combined with CVVHDF may improve the prognosis. ECLS can be recommended as a vital supportive treatment for fatal colchicine poisoning. Both G-CSF and TPO can attenuate the severity
and shorten the duration of neutropenia and thrombocytopenia. NAC can improve oxidative stress-induced cellular damage by colchicine. Colchicine-specific Fabs and engineered lipocalin (Lcn2) may be potential antidotes to reverse the toxic effects of colchicine. Much more studies are needed to certify the efficacy of these methods mentioned above.

**Funding** This work was supported by the National Natural Science Foundation of China (Grant No. 82072157, 2021), Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program (Grant No. RC200291, 2020), and 345 Talent Project of Shengjing Hospital.

**Declarations**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Human and animal rights** This article does not contain any studies with human participants or animals performed by any authors.

**Informed consent** For this type of study, formal consent is not required.

**References**

1. Slobodnick A, Shah B, Pillinger MH et al (2015) Colchicine: old and new. Am J Med 128(5):461–470. https://doi.org/10.1016/j.amjmed.2014.12.010
2. Baud FJ, Sabouraud A, Vicaut E et al (1995) Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. N Engl J Med 332(10):642–645. https://doi.org/10.1056/NEJM19950309321004
3. Boyadzhieva Z, Ruffer N, Krusche M (2021) Colchicine: old medication with new benefits: use in rheumatology and beyond. Z Rheumatol 80(7):647–657. https://doi.org/10.1007/s00393-021-01017-x
4. RECOVERY Collaborative Group (2021) Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med 9(12):1419–26. https://doi.org/10.1016/s2213-2600(21)00345-5
5. Aghabillooei A, Zanami N, Hassanian-Moghaddam H et al (2014) Acute colchicine overdose: report of three cases. Reumatismo 65(6):307–311. https://doi.org/10.4081/reumatismo.2013.720
6. Finkelstein Y, Aks SE, Hutson JR et al (2010) Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 48(5):407–414. https://doi.org/10.3109/15563650.2010.495348
7. Niel E, Scherrmann JM (2006) Colchicine today. Jt Bone Spine 73(6):672–678. https://doi.org/10.1016/j.jbspin.2006.03.006
8. Kintz P, Jamesy C, Tracqui A et al (1997) Colchicine poisoning: report of a fatal case and presentation of an HPLC procedure for body fluid and tissue analyses. J Anal Toxicol 21(1):70–72. https://doi.org/10.1093/ata/21.1.70
9. Borron SW, Scherrmann JM, Baud FJ (1996) Markedly altered colchicine kinetics in a fatal intoxication: examination of contributing factors. Hum Exp Toxicol 15(11):885–890. https://doi.org/10.1177/096032719601501104
10. Rochdi M, Sabouraud A, Baud FJ et al (1992) Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases. Hum Exp Toxicol 11(6):510–516. https://doi.org/10.1177/096032719201100612
11. Rochdi M, Sabouraud A, Girre C et al (1994) Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol 46(4):351–354. https://doi.org/10.1007/BF00194404
12. Ben-Chetrit E, Levy M (1998) Colchicine: 1998 update. Semin Arthritis Rheum 28(1):48–59. https://doi.org/10.1016/s0049-0172(98)80028-0
13. Chappey ON, Niel E, Wautier JL et al (1993) Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther 54(4):360–367. https://doi.org/10.1038/clpt.1993.161
14. Elmegily M, Youvrahis M, Guo C et al (2020) Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet 59(6):699–714. https://doi.org/10.1007/s40262-020-00867-1
15. Horn JR, Hansten PD (2015) Drug interactions with CYP3A4: an update. Pharm Times 81(12)
16. Erden A, Karagoz H, Gumuscu HH et al (2013) Colchicine intoxication: a report of two suicide cases. Ther Clin Risk Manag 9:505–509. https://doi.org/10.2147/TCRM.S54558
17. Folpini A, Furlori P (1995) Colchicine toxicity—clinical features and treatment. Massive overdose case report. J Toxicol Clin Toxicol 33(1):71–77. https://doi.org/10.3109/1556369509020219
18. Hood RL (1994) Colchicine poisoning. J Emerg Med 12(2):171–177. https://doi.org/10.1016/0736-4679(94)90695-5
19. Rahimi M, Alizadeh R, Hassanian-Moghaddam H et al (2020) Clinical manifestations and outcomes of colchicine poisoning cases; a cross sectional study. Acad Emerg Med S1(1ce53
20. Lu X, Liu Y, Wang C et al (2021) Pathogenic characteristics and treatment in 43 cases of acute colchicine poisoning. Toxicol Res (Camb) 10(4):885–892. https://doi.org/10.1039/d0tx00120f
21. Jayaprakash V, Ansell G, Galler D (2007) Colchicine overdose: the devil is in the detail. N Z Med J 120(1248):U2402
22. Cozza J, Do TVC, Ganti S et al (2021) The ugly side of colchicine. J Investig Med High Impact Case Rep 9:23247096211029744. https://doi.org/10.1177/23247096211029744
23. Harris R, Marx G, Gillett M et al (2000) Colchicine-induced bone marrow suppression: treatment with granulocyte colony-stimulating factor. J Emerg Med 18(4):435–440. https://doi.org/10.1016/s0736-4679(00)00160-5
24. Silverstein DC, Hopper K (2009) Small animal critical care medicine. Saunders/Elsevier, St. Louis
25. Decker WJ, Combs HF, Corby DG (1968) Adsorption of drugs and poisons by activated charcoal. Toxicol Appl Pharmacol 13(3):454–460. https://doi.org/10.1016/0041-008x(68)90122-1
26. Maxwell MJ, Muthu P, Prity PE (2002) Accidental colchicine overdose. A case report and literature review. Emerg Med J 19(3):265–267. https://doi.org/10.1136/emj.19.3.265
27. Cooco G, Chu DC, Pandolfo S (2010) Colchicine in clinical medicine. A guide for internists. Eur J Intern Med 21(6):503–508. https://doi.org/10.1016/j.ejim.2010.09.010
28. Atas B, Csakse H, Tancer O et al (2004) Four children with colchicine poisoning. Hum Exp Toxicol 23(7):353–356. https://doi.org/10.1177/096032710404577c
29. Putterman C, Ben-Chetrit E, Caraco Y et al (1991) Colchicine intoxication: clinical pharmacology, risk factors, features, and management. Semin Arthritis Rheum 21(3):143–155. https://doi.org/10.1016/s0049-0172(91)90003-i
30. Goodman IH (2020) Survival of a dog with accidental colchicine overdose. J Vet Emerg Crit Care (San Antonio) 30(1):74–80. https://doi.org/10.1111/vec.12919
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.